Back to Immunity
SupplementPreliminary evidenceImmunity

Gymnema sylvestre

Ayurvedic gurmar ('sugar destroyer'), preliminary RCT signal for postprandial glucose and acute reduction of sweet taste perception.

Why

Gymnema sylvestre (gurmar, literally 'sugar destroyer' in Hindi) has been used in Ayurveda for over 2,000 years as a diabetes treatment. Standardised extracts (GS4) have small RCTs and open trials reporting reductions in fasting glucose, HbA1c, and insulin requirements in type 2 diabetes (Baskaran 1990, Shanmugasundaram 1990). The acute taste-modulation effect, suppression of sweet taste perception when leaf is chewed, is mechanistically interesting but unrelated to the systemic glycaemic effect.

How it works

Gymnemic acids reversibly bind sweet taste receptors (T1R2/T1R3), basis of the acute taste suppression. Systemic glycaemic effect via increased pancreatic insulin secretion and possible β-cell regeneration (preclinical data). Reduces intestinal glucose absorption.

Expected onset · Acute taste effect immediate; systemic glycaemic effects over 6–12 weeks

How to take

Dosage

Standardised extract (GS4, 25% gymnemic acids): 200 mg twice daily. Higher doses up to 500 mg three times daily used in trials.

Timing

Before main meals to blunt postprandial glucose

On the label

Standardised GS4 extract with stated gymnemic-acid content (25%) is the trial-grade form. Crude leaf or low-standardised extract is less consistent.

Ideal for

Adults with prediabetes or mild type 2 diabetes exploring Ayurvedic adjuncts; people seeking sweet-craving reduction.

Safety

Hypoglycaemia risk additive with insulin and sulphonylureas. Monitor. May affect iron absorption. Separate from iron supplements. Pregnancy and breastfeeding: avoid (limited data). No major drug interactions documented at supplement doses.

Evidence

At a glance

Baskaran 1990 open trial (n=22 type 2 diabetes): GS4 400 mg/day reduced HbA1c and fasting glucose over 18–20 months, with insulin reduction in some patients. Pothuraju 2014 systematic review noted directionally consistent results but limited modern RCT quality. Preliminary evidence, no Cochrane review, EMA HMPC monograph or EFSA-authorised health claim covers this indication; cited RCTs are small or in non-tier-1 journals. Useful as honest reference rather than evidence-grade recommendation.

Limitations

Preliminary evidence, no Cochrane review, EMA HMPC monograph or EFSA-authorised health claim covers this indication; cited RCTs are small or in non-tier-1 journals. Useful as honest reference rather than evidence-grade recommendation.

Where to get it

Shop Gymnema sylvestre on Amazon

Sponsored · As an Amazon Associate, Healicus earns from qualifying purchases.